Intangible Assets

SIGA benefits from FDA-approved TPOXX as a countermeasure for smallpox/orthopox, which creates a regulatory barrier that peers cannot replicate quickly, but the moat is narrower than diversified pharma peers because it is tied to a single product and narrow indication set.

Government procurement and public-health stockpiling support demand visibility and reduce direct commercial substitution, but this is weaker than the entrenched formularies and physician-prescribing relationships that protect larger specialty-drug peers.

The company’s intellectual-property and regulatory position can sustain pricing power in its niche, but peer comparison is unfavorable versus firms with broader patent estates and multiple approved assets that spread competitive risk across products.

Because the asset base is concentrated in one core countermeasure rather than a portfolio of differentiated therapies, the durability of intangible advantage is real but not broad enough to score as strong versus peers.

Switching Costs

Switching costs are limited because SIGA sells a government-facing countermeasure rather than an embedded workflow product, so customers are not locked in by integration or retraining costs the way they are with software or device peers.

Once procurement specifications are met, buyers can re-source or diversify suppliers more easily than in businesses where clinical adoption, data migration, or platform dependence creates high retention.

The main friction is qualification and preparedness for emergency stockpiles, which helps retention versus generic suppliers, but this is materially weaker than the high switching costs seen at peers with recurring enterprise or hospital-system integration.

As a result, customer stickiness exists at the contract level but does not create durable, high-cost switching behavior that would materially protect margins over 5–10 years.

Network Effects

SIGA does not benefit from meaningful network effects because demand for TPOXX is driven by government preparedness decisions rather than user growth, ecosystem adoption, or data-driven product improvement.

There is no evidence of a self-reinforcing platform where more users attract more users, which leaves the company without the compounding advantage that stronger peers in software, marketplaces, or diagnostics can capture.

Peer comparison is unfavorable because even modest network effects in adjacent healthcare platforms can improve retention and pricing power, while SIGA’s product economics remain essentially linear and contract-based.

Without ecosystem feedback loops, network effects do not materially contribute to moat durability or long-term margin protection.

Cost Advantage

SIGA may benefit from focused manufacturing and a narrow product set, which can support operational simplicity, but this is not a durable scale-based cost advantage versus larger peers with broader procurement and production footprints.

The company’s low asset turnover and negative TTM ROIC suggest that any cost efficiency is not translating into superior capital productivity, which weakens the case for a structural cost moat.

Compared with diversified pharma peers, SIGA lacks the purchasing power, manufacturing breadth, and overhead absorption that typically create persistent unit-cost advantages.

Any cost edge is therefore limited to niche execution rather than a repeatable structural advantage that would reliably defend margins over time.

Efficient Scale

SIGA operates in a narrow biodefense niche where the addressable market is limited and specialized, which can reduce the number of meaningful competitors and create some efficient-scale characteristics.

The market is not large enough to support many players profitably, but this advantage is weaker than in regulated utility-like or infrastructure businesses where one or two firms can dominate a region or system.

Peer comparison is mixed because the niche focus helps SIGA avoid broad commercial competition, yet it also means the company lacks the scale depth and diversification that make efficient-scale moats more durable at stronger peers.

Efficient scale is present in a limited form, but it is not strong enough on its own to create peer-leading pricing power or retention.

Overall Score

SIGA has a real but narrow moat anchored by regulatory approval and government stockpiling demand, yet it lacks the broader switching costs, network effects, and scale advantages that would make its competitive position clearly superior to peers over 5–10 years.